Adenosine receptors are a family of G-coupled receptors which mediate the antiinflammatory and immune-suppressive effects of adenosine in a damaged tissue. A large number of evidence indicate that the accumulation of adenosine under hypoxic conditions favors tumor progression, helping cancer cells to evade immune responses. Tumor cells and/ or lymphoid and myeloid cells can express the adenosine-generating enzyme CD73 and/or A 2A receptor, which in turn strongly suppresses an effective T-cell-mediated response, while promotes the activity of suppressive cells such as Treg and myeloid-derived suppressor cells. CD73 inhibitors and A 2A antagonists, either as single agents, or in combination with immune-checkpoints inhibitors such as anti PD-1 monoclonal antibodies, are currently in Phase I clinical trial in cancer patients. Recent studies show that A 2B receptor plays an important role in mediating the pro-tumor effects of adenosine, since its selective blockade can inhibit tumor growth in some murine tumor models. Targeting A 2B receptor reduces immunosuppression induced by myeloid cells and inhibits the stromal cells activity within the tumor microenvironment, limiting tumor angiogenesis and metastatic processes. Here, the authors review the current data on involvement of A 2B receptor in regulating tumor progression and discuss the development of A 2B receptor inhibitors as potential therapeutic agents in cancer treatment.
INTRODUCTION
Tumor microenvironment is populated not only by malignant cells but also by other stromal cells and immune cells that cooperate to the development of cancer. [1, 2] In the eternal battle against cancer, several strategies have been developed. One of the first approach to treat cancer has been the antineoplastic chemotherapy which is made up of chemical substances that provide to halt directly the highly-replicating tumor cells by damaging their RNA or DNA. [3] Radiotherapy is another important treatment currently used for several tumors, through which cancer cells are either directly killed upon DNA damage by depositing high physical energy of radiation, or indirectly due to the release of free radicals. [4] Nowadays the most novel anti-cancer strategies are the targeted-therapy and immunotherapy. The cancer targeted-therapy uses small molecules that can block fundamental pathways or mutant proteins essential for tumor growth. [5] Conversely, cancer immunotherapy is a therapeutic strategy that improves the host immune response against cancer cells, instead of acting directly on tumor cells. [6] Several chromosomal alterations, genetic mutations and genomic instability that occur in cancer cells provide a different set of antigens that the immune system can use to distinguish transformed cells from their own cells. [7] However, tumor cells escape from host immune surveillance through different mechanisms, that include loss of immunogenicity and ineffective T-cell mediated responses. Moreover, several inflammatory mediators including chemokines [CCchemokine ligand 2 (CCL2), CCL5, CXC-chemokine ligand 1 (CXCL1), CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL10 and CXCL12], cytokines [tumor necrosis factor (TNF), interleukin 1 (IL-1), IL-4, IL-5, IL-6, IL-10 and IL-13] and growth factors [granulocyte macrophage-colony stimulating factor (GM-CSF), vascular endothelial growth factor (VEGF), transforming growth factor-ß (TGF-ß)] are released by tumor cells and/or stroma and immune cells surrounding tumor tissue, generating a chronic inflammatory microenvironment. Chronic inflammation in cancer can facilitate tumor proliferation and invasion and drive the recruitment and activation of immunosuppressive cells, including T regulatory (Treg) cells, myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAM). In this context, many inhibitory receptors, known as "immune checkpoint molecules" such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and programmed cell death-1 (PD-1), are upregulated on activated lymphocytes during an active immune response providing a negative feedback mechanism. [7] CTLA4 binds to members of the B7 family on antigen-presenting cells (APCs) inhibiting T-cell activation, while PD-1 interacts with ligands PD-L1, expressed on different cell types including tumor cells, or PD-L2 on macrophages and dendritic cells, inhibiting T-cell functions. [7, 8] The development of agonist antibodies (for costimulatory pathways) or antagonist antibodies (for inhibitory pathways) which target lymphocyte receptors or their ligands is one of the most promising approach with the potential to modulate the tumor microenvironment and improve the efficacy of immune response/s against cancer cells.
[8] The first class of immunotherapeutics approved by US Food and Drug Administration (FDA) for patients with metastatic melanoma includes antibodies against CTLA4 (Ipilimumab and Tremelimumab). [9] Later on other immune checkpoint molecules have been discovered, such as antibodies against PD-1 (Nivolumab, Pembrolizumab and Atezolizumab), PD-L1, lymphocyte-activation gene 3 (LAG3, also known as CD223), B7-H3 (also known as CD276), B7-H4 (also known as B7-S1, B7x and VCTN1) and T-cell immunoglobulin domain and mucin domain 3 (TIM3). [8] The therapeutic outcomes in cancer patients is improved by combining immunotherapeutics with chemotherapy. [8] The concomitant blockade of different immune checkpoints may increase the success of immunotherapy in cancer patients. [8] Hence, in the last few years many efforts have been made aiming to investigate novel therapeutic strategies to inhibit cancer-induced immune-suppression. It has become clear that in the tumor microenvironment there are several pathways that may play an important role in the tumor immune evasion process. Among them, extracellular adenosine, an ATP-derived molecule generated by the extracellular CD39/CD73 enzymes, has been identified as an immune checkpoint that critically impairs the anti-tumor immune response mainly via A 2A adenosine receptor subtype. [10] [11] [12] Accordingly, selective inhibitors of adenosine signaling pathways have been tested in pre-clinical studies [13, 14] and some of them, including the antibody anti-CD73 and the A 2A receptor antagonists are currently in Phase I clinical trials in cancer patients, either as single agents, or in combination with immune checkpoints inhibitors such as anti PD-1 monoclonal antibodies [NCT02503774 and NCT02655822].
While the role in tumor immunity of CD73-A 2A receptor axis has been extensively examined, less is known about the role of A 2B receptor subtype in tumor development and progression. Compelling evidence suggest that this receptor contributes to the pro-tumor effects of adenosine within tumor microenvironment. In this article, we review the current data on the effects of adenosine in tumor progression, focusing on the emerging role of A 2B receptor in regulating tumor growth and discuss the therapeutic potential of targeting A 2B receptors in cancer treatment.
CRITICAL ROLES OF ADENOSINE IN TUMOR PROGRESSION
Adenosine is a key endogenous molecule produced at the extracellular level by two ectoenzymes, ecto-5'-nucleotidase (CD73) and ectonucleoside triphosphate diphosphohydrolase-1 (CD39) physiologically expressed on both hematopoietic and nonhematopoietic cell types. [15, 16] Once released in the extracellular space, adenosine elicits its physiological responses by coupling and activating four membrane adenosine receptors (A 1 , A 2A , A 2B , A 3 ) which contain seven transmembrane domains coupled to G proteins. [17] Once bounded with its receptors, adenosine can inhibit (via A 1 and A 3 ) or stimulate (via A 2A and A 2B ) the adenylyl cyclase resulting in a decrease or increase in cyclic AMP (cAMP) accumulation, respectively. [18] cAMP activates the protein kinase A (PKA) and in turn the nuclear substrate cAMP responsive elementbinding protein (CREB) that regulates the expression of several genes by binding to cAMP responsive elements and other cAMP effectors such as Epac, altering pro-inflammatory genes expression. [19] [20] [21] [22] A 2B receptor can also activate the phospholipase C (PLC) by coupling Gq protein. [23, 24] All adenosine receptors are involved in the modulation of mitogen-activated protein kinase (MAPK) activity. [25] The tumor milieu is characterized by high levels of adenosine triphosphate (ATP) due to the high proliferating rate of cancer cells. The ATP is rapidly converted at the extracellular level in ADP and AMP through two reversible steps via CD39, while the last irreversible step in adenosine is mediated by CD73. [16] Under homeostatic conditions adenosine level is low but during pathophysiological events (including stress, infection, inflammation and cancer) extracellular adenosine levels can be increased from 10-200 nmol/L up to 10-100 μmol/L. [26] In inflammatoryassociated conditions, adenosine typically attenuates the inflammatory response. [26, 27] Importantly, studies by Ohta and Sitkovsky [28] showed for the first time that A 2A receptor-deficient mice are unable to control inflammation, resulting in exaggerated immune responses which can trigger extensive tissue disruption with subsequent cell death. These effects of adenosine are dependent on the activation of the adenosine A 2A receptors on immune cells, which induce a wide range of singular immunosuppressive responses which regulate the uncontrolled inflammation to harmful insults. [27, 29, 30] However, in the context of tumor while extracellular ATP increases the T-cell mediated effector function, high levels of adenosine mediates opposite effects favoring immune suppression that is associated with tumor growth and metastasis. [31] Hypoxia, which is a common feature of the tumor microenvironment that promotes immunosuppression, is one of the main factors responsible of the increased production of adenosine within many solid tumors. [11] Indeed, the expression and the enzymatic activities of CD39 and CD73, responsible of the adenosine generation, increased under hypoxic conditions, while the expression of the adenosine kinase, which inhibits the metabolism of adenosine, is down-regulated. [11] At the same time, the expression of adenosine receptors A 2A and A 2B is also up-regulated. [32] Consequently, adenosine along with other HIF-induced immunosuppressive factors and cells, contributes to modulate the functions of tumor cells, tumor-infiltrating immune cells and/or other stroma cells.
Within the hematopoietic compartment, CD39 is expressed on B cells and monocytes, subsets of CD8 + T cells, CD4 + T cells and NK cells. [15, 33] CD73 is expressed on B cells and subsets of CD8 + T cells, CD4 + T cells and NK cells and small subsets of monocytes. [15, 33] CD39 and CD73 are co-expressed on B cells, Treg cells, Th17 cells, NK cells, neutrophils, tissue macrophages and myeloid-derived suppressor cells (MDSCs). [15, 33] CD39 and CD73 are also expressed on endothelial cells and on the surface of several types of cancer cells. [14, 15] Thus, CD73-expressing cells, including immune cells and/or stroma cells, produce adenosine that accumulate in the tumor microenvironment and profoundly impairs anti-tumor immune responses. Accordingly, a large number of evidence have proved that targeting adenosine-generating enzymes significantly reduces tumor growth by improving antitumor immune responses.
A 2A receptor is the most thoroughly characterized receptor involved in the adenosine-induced antiinflammatory/immune-suppressive effects within the tumor microenvironment. A 2A receptor is highly expressed on lymphocytes, macrophages, dendritic cells, NK cells, and neutrophils. Activation of A 2A receptor significantly reduces T-cell receptor (TCR)-triggered effector functions, including proliferation and production of cytokines and chemokines, preventing T cells activation and function via cAMP/ protein kinase cAMP-dependent (PKA) pathways. [34] [35] [36] These effects occurs upon A 2A adenosine receptor stimulation in naïve CD4 + T cells as well as in CD8 + T cells. Furthermore, A 2A receptor stimulation reduces the expression of CD25 and CD40 ligand (CD40L) and increases the expression of PD-1 and CTLA-4 on T cells, [37] inducing T cell anergy that promotes peripheral tolerance. [35] Stimulation of A 2A receptor on myeloid cells can also affect the release of IL-12 and induce the production of IL-10, [38] affecting significantly the T-and NK-cell responses in the solid tumor microenvironment. [39] Additional evidence also show that A 2A adenosine receptor stimulation promotes the development of immune suppressive myeloid cells [40] or Treg cells. [41] The first in vivo genetic evidence of the role of A 2A receptor in tumor progression has been reported by Ohta et al. [10] who showed that 60% of A 2A receptor deficient mice completely rejected established immunogenic tumors in a CD8 + T-celldependent manner. However, 40% of tumor-bearing A 2A receptor deficient mice did not reject the tumor, possibly because of the expression of A 2B receptor on A 2A receptor deficient CD8 + T cells. [10] At the same time a large number of evidence show that inhibition of CD73 activity or CD73 knockdown on tumor cells inhibit tumor growth and metastasis by enhancing the anti-tumor T cell response. [42] [43] [44] [45] [46] CD73-deficient mice are resistant to tumor and show an increased influx of CD8 + T cells [44] and low number of Tregs within the tumor. [47] The expression of CD73 on various tumor cells from cancer patients, including breast, [46] glioblastoma, [48] prostate, [49] ovarian, [50] leukemia [51] has been associated with poor prognosis. Notably, some chemotherapeutics are able to increase the expression of CD73 on cancer cells, which may in turn represent a putative mechanism of resistance to chemotherapeutics. [46, 49, 51] On the other hand, targeting CD73 can improve the therapeutic potential of some conventional cancer treatments, including chemotherapy, radiotherapy and immunotherapy. For example, inhibition of CD73 in combination with doxorubicin prolonged the survival of mice with metastatic breast cancer. [46] Adenosine can also impair the anti-tumor response induced by high dose of radiation therapy. [52] Administration of CD73 inhibitor into mice with tumors exposed to radiation therapy can significantly reduce tumor growth. [52] Notably, inhibition of CD73 may also improve the synergy of radiation therapy in combination with anti-CTLA4 monoclonal antibody. [52] Recent studies indicate that inhibition of adenosine/ A 2 adenosine receptors axis synergizes with other immune checkpoints inhibitors reducing potently tumor growth in murine models of cancer. In particular, treatment of mice with monoclonal antibody anti-CD73 enhances the anti-tumor effects of antibodies anti-PD1 and anti-CTLA4. [53] In support, other studies have demonstrated that selective blockade of A 2A adenosine receptor in combination with anti PD-1 antibody and anti-CTLA4 antibody potently reduced tumor growth. [54] [55] [56] The therapeutic synergy of these combinations depends on the CD73 expression on tumor cells, proving that CD73-generating adenosine by tumor cells within the tumor microenvironment may affect the activity of immunotherapy. Furthermore, blockade of PD-1 enhances the expression of A 2A receptors on tumor-infiltrating CD8 + T cells, suggesting that adenosine via A 2A receptor limits the immune response against cancer induced by inhibitors of immune checkpoints. [54] More recently, it has been demonstrated that blockade of A 2B adenosine receptor subtype with a selective antagonist improves survival and the anti-metastatic effects of anti-PD1 and anti-CTLA4 monoclonal antibodies in both melanoma and mammary cancer models of metastasis with cells expressing CD73. [57] The anti-metastatic effects of these combinations relies on the capacity of immune checkpoints inhibitors to boost immune responses and on direct effects of A 2B adenosine receptor inhibitor on cancer cell metastasis. [57] Here the authors show that blockade of A 2B receptor in A 2B receptor deficient mice is able to reduce the metastasis of human triple negative breast cancer (TNBC) xenografts, confirming the critical role of A 2B receptor on cancer cells rather than host cells. [57] Altogether these preclinical studies strongly support the therapeutic potential of targeting adenosine in cancer.
Experimental evidence suggests that also CD39 can represent a potential therapeutic target for cancer treatment. CD39 is highly expressed by Treg cells and together with CD73 generate adenosine in the tumor microenvironment. [58] Elevated levels of CD39-expressing Treg cells have been found in some mouse tumor tissues, including melanoma and colorectal cancer. [58] Inhibition of CD39 reduces the tumor growth, enhances the recruitment of T cells in the tumor lesions and improves the effector functions of CD8 + T cells and NK cells, by impairing the activity of CD39-expressing Treg cells. [58] Although additional studies are needed to better clarify the therapeutic potential of targeting CD39 in cancer, the use of CD39 inhibitors might be useful to limit the immune suppression induced by Treg cells.
Selective agonists of A 3 adenosine receptor subtype have proved to directly inhibit proliferation of A 3 -expressing tumor cells by arresting cell cycle progression and exert immunostimulatory effects in some murine tumor models in a NK-and T-celldependent manner, enhancing the production of Th1-like cytokines in the tumor microenvironment. [59] [60] [61] [62] [63] A 3 adenosine receptor agonists have been tested indeed in some clinical trials for rheumatoid arthritis (NCT00280917, NCT00556894, NCT01034306, NCT02647762), [64] hepatocellular carcinoma (NCTNCT00790218, NCT02128958) and hepatitis (NCT00790673), [65] dry eye syndrome (NCT01235234, NCT00349466) [66] and psoriasis (NCT01265667). [67] Nonetheless, emerging evidence suggest that A 2B receptor can mediate the pro-tumor effects of adenosine. It is known that A 2B receptor is important in some patho-physiological conditions, including vascular injury, [68] chronic lung disease, [69] vascular leak, [70] and ischemic disease. [71] First studies performed by Ryzhov et al. [72] in 2008 show that tumor growth in A 2B receptor deficient mice was reduced compared to that observed in wild type mice, providing the first genetic evidence for a pivotal role of A 2B receptor in tumor progression.
Up to now a number of selective A 2B receptor antagonists (such as MRS1754, ATL801, GS-6201, PSB603 and PSB1115) and selective A 2B agonists (Bay60-6583) have been synthesized, helping the study and the characterization of the role of this adenosine receptor in many patho-physiological conditions, including cancer, as discussed below.
EXPRESSION OF A 2B RECEPTOR
A 2B adenosine receptor is widely expressed in the entire organism, although its role is not completely understood. The A 2B receptor expression has been detected in type II alveolar epithelial cells, [73] endothelial cells, [74] chromaffin cells, [75] astrocytes, [76] neurons, [77] and taste cells. [78] Moreover, A 2B receptor is expressed also on many immune cell populations including mast cells, [79] neutrophils, [70] dendritic cells, [80] macrophages, [74] and lymphocytes. [81] Despite A 2B receptor binds adenosine with lower affinity (EC 50 = 24 μmol/L) than A 2A receptor, [72, 82] its relevance in regulating tumor growth is becoming clear both because its expression is highly influenced by the tumor milieu and because A 2B receptor can play different physiological roles compared to A 2A receptor.
The tumor microenvironment is characterized by high proliferating rate of cancer cells which contribute to hypoxia condition. Hypoxia is a very strong stimulus for up-regulating A 2B receptor expression through hypoxia inducible factor (HIF-1α) and hypoxia-dependent signaling pathways in endothelial cells, dendritic cells (DCs), muscles, fibroblasts and T cells. [32, [83] [84] [85] [86] [87] Indeed, a functional hypoxia-responsive region within the A 2B receptor promoter has been identified, confirming the selective transcriptional induction A 2B receptor by hypoxia. [87] Transcription of A 2B receptor can be induced by bacterial lipopolysaccharide (LPS) or interferon (IFN)-γ in macrophages, [88, 89] by TNF-α in vascular smooth muscle cells, [90] and by IL-1β in endothelial cells. [91] Furthermore, a post-transcriptional regulation of A 2B receptor by inflammatory mediators has been demonstrated in endothelial and pulmonary epithelial cells [92] and in colonic epithelial cells. [93] Therefore, although A 2B is a low-affinity adenosine receptor, under inflammatory-hypoxic conditions, its expression is up-regulated while the concentration of adenosine reaches highest levels. In this context, the A 2B receptor may play an important role in mediating adenosineinduced pathological effects.
A 2B RECEPTOR AND TUMOR IMMUNITY
Although the role of A 2B receptor in controlling T-cellmediated response is not completely clear, compelling evidence indicate that this receptor may influence the features of some immune cell populations.
It has been demonstrated that A 2B receptor is involved in the differentiation of T cells under Treg skewingconditions, since its inhibition is able to suppress the expression of FoxP3 and IL-10 production in a way completely independent from T cell activation. [94] To be activated and provide anti-tumor responses CD4 + T-cells need the expression of the major histocompatibility complex (MHC) class II. In several types of tumors, the loss of MHC class II is related to impaired levels of CD4 + T-cells. [95] Moreover, the levels of either MHC class II or class II transactivator (CIITA) are altered in highly metastatic cancer cells. [96] A 2B receptor stimulation by repressing CIITA can impair MHC class II transcription in IFN-γ-stimulated cells. [97, 98] Moreover, bone marrow-derived dendritic cells (BMDCs) express A 2B receptor and adenosine inhibits BMDCs IL-12p70 production via A 2B receptor. Depending on the levels of this cytokine, CD4 + T-cells can differentiate into Th1 or Th2 cells. [99] The impaired production of pro-inflammatory cytokines (TNF-α and IL-12) and the increased IL-10 production induced by A 2B receptor activation leads to a lower expression of CD86 and MHC class II lowering CD4 + T cell stimulation. [100] A 2B receptor can also affect macrophages proliferation induced by macrophage colony-stimulating factor (M-CSF) [101] and the differentiation of human monocytes, mouse peritoneal macrophages and hematopoietic progenitor cells (HPCs) into myeloid DCs with tolerogenic and angiogenic features. [80] A 2B receptor activation promotes the expansion in vitro of MDSCs, that contribute to induce immunosuppression by producing adenosine. [102] MDSCs potently suppress anti-tumor T-cell response and/or promote angiogenesis. [103] Altogether, these studies strongly support a role of A 2B receptor in inducing the differentiation of hematopoietic progenitor cells into mature cells with tolerogenic and suppressive features. Subsequent studies performed in vivo show that A 2B deficient mice have reduced amounts of tumor-infiltrating myeloid cells CD11b high /Gr-1 high , suggesting that A 2B receptor suppresses immune surveillance. [72] Later, Cekic et al. [104] showed that the selective blockade of A 2B receptor inhibits bladder and breast tumor growth in mice, by inducing a T-cell mediated response in a CXCR3-dependent manner. In a mouse model of melanoma, selective blockade of A 2B receptor inhibits tumor growth. [105] This effect was associated with lower levels of IL-10 and MCP-1 in the tumor tissue and reduced accumulation of tumor-infiltrating MDSCs. [105] Notably, the levels of MDSCs in secondary lymphoid organs remained unchanged in mice treated with the selective A 2B receptor antagonist, consistent with a selective activity of the antagonist on the recruitment of MDSCs to tumor lesions rather than with a putative systemic effects. [105] Blockade of A 2B receptor within the tumor microenvironment modulates the intratumoral levels of various inflammatory mediators and growth factors that could in turn influence the features of tumor-infiltrating immune cells, promoting the recruitment/accumulation of MDSC. [106] Accordingly, the percentage of tumor-infiltrating CD8+ T cells upon A 2B receptor blockade enhanced in the tumor lesions. [105] Furthermore, treatment of mice with the A 2B receptor antagonist PSB1115 in combination with dacarbazine, a chemotherapeutic agent commonly employed in melanoma patients, reduces tumor growth and significantly increases the number of CD8 + T cells in the melanoma lesions demonstrating the high potential of combining A 2B receptor blockade and chemotherapy for cancer treatment. [105, 106] In conclusion, the experimental evidence in some tumor mouse models suggest that the selective blockade of A 2B receptor may ameliorate T cell-mediated immune surveillance by impairing the accumulation of suppressive cells and the levels of inflammatory factors in the tumor microenvironment. [72, [104] [105] [106] However, despite the relevance of these observations, more studies are needed to provide a detailed understanding of the role of A 2B receptor in modulating the immune responses in tumor environments.
A 2B RECEPTOR AND TUMOR STROMA
A number of studies indicate that A 2B receptor can directly affect the proliferation/migration of tumor cells and the function of other stroma cells that populate the tumor niche, including endothelial cells and fibroblasts.
A critical role for A 2B adenosine receptor in mediating proliferation and/or apoptosis in different cancer cell lines has been delineated. A 2B adenosine receptor is highly expressed in prostate cancer cell lines and selective antagonist of A 2B adenosine receptors or silencing A 2B receptors blocked the proliferative effects induced by a non-selective adenosine analog NECA. [107, 108] Other studies indicate that A 2B adenosine receptor is highly expressed also in oral squamous carcinoma cell lines, as well as in human oral carcinoma tissues, where its expression is correlated with those of HIF-1. [109] Studies by Gessi et al. [110] demonstrate that in colon cancer cells, although at the mRNA levels A 2B receptor is more expressed than A 1 , A 2A and A 3 , the density of A 3 receptors is the highest among the adenosine receptor subtypes. Later, other studies have demonstrated that the adenosine A 2B receptor is up-regulated in colorectal carcinoma tissues and colon cancer cell lines compared with normal colorectal mucosa under hypoxic conditions. [111] Antagonists of A 2B receptors inhibit cancer cell proliferation, suggesting that this receptor may be a potential therapeutic target for colorectal cancer. [111] In contrast, in gastric cancer cells A 2B adenosine receptor has been identified as target of miR128b, a proto-oncogene miRNA down-regulated in gastric cancer tissues. [112] In this work, the authors demonstrate that the down-regulation of miR-128b in gastric cancer cell is associated with an overexpression of A 2B adenosine receptor and decreased cell apoptosis rate. [112] In osteosarcoma cells it has been demonstrated that p73 upregulates A 2B adenosine receptor and A 2B receptor agonists can enhance p73-dependent cell death in response to chemotherapy. [113] Moreover, stimulation of A 2B receptor with a non-selective adenosine analog NECA induces apoptosis in ovarian cancer cells. [114] Nonetheless,while a number of studies demonstrate that stimulation of A 2B adenosine receptor in some cancer cell types promotes proliferation, whereby knockdown or pharmacological inhibition of this receptor reduces tumor cell growth and promotes apoptosis, [107] [108] [109] [110] [111] opposite results have been also described. [112, 113] The discrepancy might likely depend on the cancer cell types, the expression levels of this receptor on tumor cells and the selectivity and/or concentrations of pharmacological tools used in the experimental settings.
It has been demonstrated that agonists of A 2B receptor induce anti-proliferative and pro-apoptotic effects on glioblastoma cancer stem cells (CSCs). [115] Furthermore, stimulation of A 2B receptors as well as A 1 receptors sensitize glioblastoma CSCs to chemotherapy. [115] A role of A 2B receptor in promoting the migration of tumor cells in vitro and in vivo has been clearly demonstrated. Indeed, a number of studies show that adenosine may directly influence the migration/ invasion of tumor cells via A 2B adenosine receptor. Stagg et al. [42] have demonstrated that targeting the adenosine-generating enzyme CD73 inhibits tumor growth in mice and significantly delays the development of spontaneous lung metastasis.While the effect of anti-CD73 monoclonal antibody therapy on primary tumor growth relays on its capacity to improve immune surveillance, the anti-metastatic effects to the lungs is rather dependent on a direct effect of CD73-generating adenosine on breast tumor-cell migration via A 2B adenosine receptors stimulation. [42] Consistent with the role of A 2B receptor in promoting metastasis of breast cancer cells to the lung, administration of selective or non-selective A 2B receptor antagonists into mice significantly reduced metastasis burden. [42, 104] Furthermore, antagonists of A 2B receptor preferentially inhibits the invasive capacity of breast cancer cells expressing Fos-related antigen-1 (Fra-1), a transcription factor overexpressed in human metastatic breast cancers. [116] Therefore, the authors suggest that Fra-1 activity is a prognostic indicator of both breast cancer metastasis and responsiveness to pharmacological inhibitors, such as A 2B receptor antagonists. [116] In a recent paper it has been demonstrated that high expression of A 2B receptor is associated with poor survival in triple negative breast cancer (TNBC) patients. [57] As mentioned above, these authors demonstrate that A 2B receptor antagonist prevents metastasis of A 2B receptor-expressing tumor cells and improves survival when administered in combination with chemotherapeutic agents and immune checkpoints inhibitors monoclonal antibodies in both experimental and spontaneous murine models of metastasis. [57] The anti-metastatic effects of A 2B receptor antagonists is independent on lymphocytes and myeloid cells, whilst tumor A 2B receptor is critical. [57] These evidence highlight that A 2B receptor may be an attractive target for treatment of breast metastasis.
A 2B adenosine receptor can also contribute to the proangiogenic effects of adenosine in the tumor milieu. Vascular endothelial growth factor (VEGF) is a wellknown mediator critically involved in tumor progression and angiogenesis. [117] A number of studies linked VEGF production to adenosine A 2B receptor in human endothelial cells, [118, 119] in some tumor cell lines [120, 121] and in host immune cells, including dendritic cells and myeloid-derived suppressor cells. [72, 80, 122] A 2B receptor is expressed on human endothelial cells and its stimulation promotes the expression of several pro-angiogenic factors, including VEGF, IL-8 and basic fibroblast growth factor (bFGF). [118] Importantly, under hypoxic conditions the expression of A 2B receptor in endothelial and smooth muscle cells increased and the stimulation of these receptors further enhance VEGF release. [119] Hypoxia is a common feature of tumor and can induce angiogenesis. At the same time, adenosine, whose levels became elevated during hypoxia, further enhances angiogenesis by stimulating A 2B receptors, creating a positive feedback between hypoxia, adenosine and VEGF.
Other studies also indicate that adenosine promotes the release of angiogenic factors, namely VEGF and IL-8, in some cancer cells lines, via A 2B receptor including human melanoma cells [120] and glioblastoma cells, which express high levels of A 2B receptor under hypoxic conditions. [121] Using A 2B receptor deficient mice, Ryzhov et al. [72] firstly demonstrated the critical role of A 2B receptor in modulating the VEGF levels in tumor tissues. Importantly, vascularization and tumor tissue VEGF levels were significantly reduced in A 2B receptor deficient mice compared with WT mice. [72] This effect was associated with reduced tumor infiltration of VEGF-producing myeloid cells, suggesting that A 2B receptor can modulate the release of VEGF either from tumor cells and from host tumor-infiltrating immune cells, [72] that can contribute to promote tumor angiogenesis. [123] As mentioned above, adenosine promotes the differentiation of dendritic cells precursors into a subset of DC that produce angiogenic factors, including VEGF, and other immunosuppressive factors via A 2B adenosine receptor. [80] Notably, A 2B -stimulated dendritic cells are able to promote tumor growth when injected into mice. [80] These observations strongly suggest that adenosine sustains tumor angiogenesis during tumor growth by stimulating the release of VEGF from endothelial cells, tumor cells and immune cells. Accordingly, targeting CD73 in mice impairs tumor angiogenesis and decreases VEGF levels, at least in part by lowering adenosine generation in tumor environment that activates A 2B receptors. [124] Therefore, targeting CD73 and/or A 2B receptor may represent a potential therapeutic strategy to block angiogenesis. In support of this, the pharmacological blockade of A 2B receptor with a selective antagonist in mice significantly reduces the tumor levels of VEGF and CD31 positive cells within tumor lesions. [122] Moreover, the anti-angiogenic effect of A 2B receptor antagonists is, at least in part, dependent on the lower frequency of tumor-infiltrating suppressive myeloid cells (MDSCs), [72, 122] breaking the positive feedback loop that promotes angiogenesis and MDSC-mediated immune suppression in the tumor environment. Recent evidence indicate that A 2B receptor stimulation promotes the release of FGF-2 and C-X-C motif chemokine ligand 12 (CXCL12) from tumor-associated fibroblasts, [125] that contribute to promote tumor growth and angiogenesis. [126] These effects are associated with reduced expression of fibroblast activation protein (FAP), a common marker of tumor-activated fibroblasts termed cancer-associated fibroblasts (CAF), that promote tumor growth enhancing tumor immune evasion and tumor vascularization. [127] A 2B receptor-induced CXCL12 by tumor-associated fibroblasts contributes to the pro-angiogenic effects of A 2B receptor via CXCR4, suggesting a link between tumor fibroblasts and endothelial cells. [127] Moreover, fibroblasts express CD73, which is up-regulated under hypoxic conditions. [127] Altogether, these evidence suggest that in the context of tumor A 2B receptor contributes to mediate multiple effects of adenosine on different types of cells that populate the tumor niche. Furthermore, blockade of A 2B receptor modulates the intra-tumoral levels of paracrine factors, which are critical in regulating intercellular crosstalk in the tumor microenvironment.
Although the predominant role of A 2A receptor in mediating the immunosuppressive effects of adenosine in the tumor tissue and the high therapeutic potential of blocking adenosine generation and the A 2A -mediated effects, by using anti-CD73 monoclonal antibodies and A 2A selective antagonists, respectively, it is becoming clear that A 2B receptor may significantly affect tumor progression and metastasis. Its contribute to tumor development and growth is most likely dependent on its high expression levels on tumor cells, and/or endothelial cells and/or other tumor-infiltrating cells, in a rich adenosine environment.
CONCLUSION
Adenosine plays a critical role in tumor immunity, angiogenesis and metastasis process. Strategies aimed to inhibit tumor adenosine production and functions, by using CD73 inhibitors and selective blockade of A 2A adenosine receptor, are effective for cancer treatments, especially in combination with chemotherapeutic agents and immune-checkpoints inhibitors.
Nonetheless, compelling evidence support the role of A 2B receptor subtype in contributing to the pro-tumor effects of adenosine within the tumor Figure 1 ]. Despite these evidence, further studies are needed to better investigate thoroughly the mechanisms by which blockers of this receptor limit tumor growth. Understanding the relative role of A 2B receptor in tumor, depending on the cell types, on its distribution and expression, will help to potentially apply A 2B receptor-targeting agents for cancer treatment.
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